[EN] FUSED RING COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS CYCLIQUES CONDENSÉS ET UTILISATION DE CEUX-CI
申请人:TAKEDA PHARMACEUTICAL
公开号:WO2009125873A1
公开(公告)日:2009-10-15
The present invention aims to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. The present invention provides a glucokinase activator containing a compound represented by the formula (I): wherein each symbol is defined in the specification, or a salt thereof or a prodrug thereof.
Highly Practical Methodology for the Synthesis of <scp>d</scp>- and <scp>l</scp>-α-Amino Acids, <i>N</i>-Protected α-Amino Acids, and <i>N</i>-Methyl-α-amino Acids
作者:Andrew G. Myers、James L. Gleason、Taeyoung Yoon、Daniel W. Kung
DOI:10.1021/ja9624073
日期:1997.1.1
step the asymmetric alkylation of pseudoephedrine glycinamide (1) or pseudoephedrine sarcosinamide (2). Practical procedures for the synthesis of 1 and 2 from pseudoephedrine and glycine methyl ester or sarcosinemethyl ester, respectively, are presented. Optimum protocols for the enolization and subsequent alkylation of 1 and 2 are described. Alkylation reactions of 1 and 2 are found to be quite efficient
Enamine derivatives of formula (1) are described:
1
wherein
R
1
is a group Ar
1
L
2
Ar
2
Alk- in which Ar
1
is an aromatic or heteroaromatic group, L
2
is a covalent bond or a linker atom or group, Ar
2
is an arylene or heteroarylene group and Alk is a chain —CH
2
—CH(R)—, —CH═C(R)— or
2
in which R is a carboxylic acid or a derivative or biostere thereof;
R
2
is a hydrogen atom or a C
1-6
alkyl group;
Cy is a cycloaliphatic or heterocycloaliphatic ring in which X is a N atom or a C(R
w
) group;
R
x
is a oxo, thioxo, or imino group;
R
w
and R
z
is each a hydrogen atom or optional substituent;
provided that Cy is not a cyclobutenedione group;
and the salts, solvates, hydrates and N-oxides thereof.
The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders, or disorders involving the inappropriate growth or migration of cells.
Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary
申请人:California Institute of Technology
公开号:US05760237A1
公开(公告)日:1998-06-02
A practical synthesis of the potential chemotherapeutic agent L-azatyrosine is described. The key step involved the alkylation of (R,R)-(-)-pseudoephedrine glycinamide with 5-benzenesulfonyloxy-2-iodomethylpyridine and proceeded in 70-95% yield and 89-95% de. Simultaneous hydrolysis of the auxiliary and the benzenesulfonate protecting group afforded L-azatyrosine of .gtoreq.99% ee in 73% yield on multigram scale (recovery yield of (R,R)-(-)-pseudoephedrine: 90%).
Evaluation of the Efficiency of the Chiral Quaternary Ammonium Salt β-Np-NAS-Br in the Organic-Aqueous Phase-Transfer Alkylation of a Protected Glycine Derivative
allylation of glycine tert-butyl ester benzophenone Schiff base (1). This revealed the practical conditions for the asymmetric synthesis of both natural and unnatural α-amino acids, whose usefulness was demonstrated by the formal enantioselective synthesis of antibioticL-azatyrosine.